Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Celcuity Inc Market Cap
The Celcuity Inc (CELC) share price is expected to increase by 95.02% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered CELC. Price targets range from $23 at the low end to $39 at the high end. The current analyst consensus for CELC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assignedCELC 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Celcuity Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CELC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CELC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Oliver McCammon LifeSci Capital | Outperform | $27 | Initiates | Aug 26, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $27 | Reiterates | Aug 15, 2024 |
| Gil Blum Needham | Buy | $23 | Reiterates | Aug 15, 2024 |
| Bradley Canino Stifel | Buy | $39 | Maintains | Aug 15, 2024 |
| Andrew Berens Leerink Partners | Outperform | $29 | Initiates | Jul 22, 2024 |
| Gil Blum Needham | Buy | $23 | Maintains | May 31, 2024 |
| Gil Blum Needham | Buy | $24 | Reiterates | May 16, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $27 | Reiterates | May 16, 2024 |
| Alexander Nowak Craig-Hallum | Buy | $27 | Assumes | May 16, 2024 |
| Bradley Canino Stifel | Buy | $40 | Maintains | May 16, 2024 |
| Gil Blum Needham | Buy | $24 | Reiterates | Apr 12, 2024 |
| Alexander Nowak Craig-Hallum | Buy | $25 | Maintains | Mar 28, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $27 | Reiterates | Mar 28, 2024 |
| Gil Blum Needham | Buy | $24 | Maintains | Mar 28, 2024 |
| Bradley Canino Stifel | Buy | $40 | Initiates | Feb 22, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $27 | Initiates | Dec 8, 2023 |
| Gil Blum Needham | Buy | $23 | Maintains | Nov 13, 2023 |
| Gil Blum Needham | Buy | $25 | Reiterates | Sep 22, 2023 |
| Gil Blum Needham | Buy | $25 | Reiterates | Aug 11, 2023 |
| Gil Blum Needham | Buy | $25 | Reiterates | May 16, 2023 |
When did it IPO
2017
Staff Count
55
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Brian F. Sullivan
Market Cap
$626.2M
In 2023, CELC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CELC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 20 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Celcuity (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fri, 16 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Celcuity Inc. (NASDAQ:CELC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 AM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Tara Bancroft - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2024 Financial Results Conference Call. At this time all lines are in listen-only mode.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the second quarter ended June 30, 2024 and other recent business developments.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Fri, 05 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks.
Mon, 03 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
